Virolock Technologies was spun out of Penn State to commercialise a portable device that boosts early detection of viral infections.

Cambridge Enterprise and Cambridge Innovation Capital both participated in the funding round, which is based on research at the Cambridge Institute for Medical Research.

Sosei will pay $45m for a 25% stake in RNA therapy developer Mina Therapeutics and could buy the NTNU spinout outright for about $180m more.

Exploiting research conducted at Navarra University and Harvard Medical School, Vivet Therapeutics is working on gene therapies for metabolic diseases.

Amgen Ventures has come on board as an investor in genomics services platform Wuxi NextCode, in a round co-led by Temasek and Yunfeng Capital.

Sosei will pay $45m for a 25% stake in RNA therapy developer Mina Therapeutics and could buy the company outright for about $180m more.

Stem cell transplantation technology developer Magenta Therapeutics has closed a $50m series B round led by GV that included Access Industries and Partners Healthcare.

The company has revealed several additions to its GPU Ventures portfolio, including Abeja, Datalogue, TempoQuest and Zebra Medical.

The Paris-Saclay Seed Fund has participated in a funding round for Damae Medical, which has developed technology to detect skin cancer without the need for biopsies.